Allena Pharmaceuticals, Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2022 | $4 M | No. 3 | $2 to $10 million | options | SEC | |
| Nov 2015 | $51 M | No. 2 | $50 to $250 million | equity | SEC | |
| Oct 2014 | $25 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Allena Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (May 2022).
SEC Form D · May 2022
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · May 2022
That is all the official record says: Allena Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
13 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Bessemer Venture Partners VII Institutional L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Bessemer Venture Partners VII L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| BVP VII Special Opportunity Fund LP | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Deer VII & Co. L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Deer VII & Co. Ltd. | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| FHM VI, L.L.C. | Other | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| FHM VI, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Frazier Healthcare VI, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Hadley Harbor Master Investors (Cayman) L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| HBM BioCapital II LP | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Third Rock Ventures GP II, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| Third Rock Ventures II, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
| TRV GP II, LLC | Other | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 8 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Louis Brenner, M.D. | Executive officer | May 2022 |
| Richard D. Katz, M.D. | Executive officer | May 2022 |
| Alexey Margolin | Executive officer | Dec 2015 |
| Louis Brenner | Executive officer | Dec 2015 |
| Alexey D. Margolin | Director | May 2022 |
| Allene D. Diaz | Director | May 2022 |
| Ann C. Miller | Director | May 2022 |
| Gino D. Santini | Director | May 2022 |
| Louis Brenner, M.D. | Director | May 2022 |
| Mark C. Fitzpatrick | Director | May 2022 |
| Alexey Margolin | Director | Dec 2015 |
| Axel Bolte | Director | Dec 2015 |
| Gino Santini | Director | Dec 2015 |
| James Topper | Director | Dec 2015 |
| Robert Tepper | Director | Dec 2015 |
| Stephen Kraus | Director | Dec 2015 |